pa.NTIDFDA: Power analysis for scaled ABE for NTIDs according to FDA

Description Usage Arguments Details Value Warning Note Author(s) References See Also Examples

View source: R/pa.NTID.R


An analysis tool for exploration/visualization of the impact of expected values (CV, theta0, reduced sample size due to drop-outs) on power of BE decision via scABE for narrow therapeutic drugs (NTIDs) if these values deviate from the ones assumed in planning the sample size of the study.
The only implemented design is the full replicate design "2x2x4" according to the FDA Warfarin guidance.


pa.NTIDFDA(CV, theta0 = 0.975, targetpower = 0.8, minpower = 0.7, ...)



Coefficient of variation of the intra-subject variabilities of Test and Reference as ratio (not percent).
Here only the case CVwT=CVwR is implemented, i.e., CV has to be a scalar.


‘True’ or assumed T/R ratio. Often named GMR.
Must be given as ratio. Defaults here to 0.975.


Power to achieve at least in sample size estimation. Must be >0 and <1.
Typical values are 0.8 or 0.9. Defaults to 0.8.
Note that targetpower < 0.5 doesn’t make much sense.


Minimum acceptable power to have if deviating from assumptions for sample size plan.
Has to be lower than targetpower. Defaults to 0.7.
minpower < 0.5 doesn’t make much sense.


More arguments to pass to power.NTIDFDA().
F.i., alpha, theta1, theta2 or nsims if other values than the defaults for these arguments are needed.
See man page of power.NTIDFDA().


Power calculations are done via power.NTIDFDA() and calculations of CV and theta0 which result in minpower are derived via uniroot().
While one of the parameters (CV, theta0, n) is varied, the respective two others are kept constant. The tool shows the relative impact of single parameters on power.
The tool takes a minimum of 12 subjects into account as demanded in most BE guidances. However, it should be kept in mind that the FDA requires at least 24 subjects to be enrolled in studies intended for reference-scaling.

It should be kept in mind that this is not a substitute for the “Sensitivity Analysis” recommended in ICH-E9. In a real study a combination of all effects occurs simultaneously. It is up to you to decide on reasonable combinations and analyze their respective power.


Returns a list with class 'pwrA' with the components


A data.frame with the result of the sample size estimation. See output of sampleN.NTIDFDA().


A data.frame with value pairs CV, pwr for impact of deviations from CV.


A data.frame with value pairs theta0, pwr for impact of deviations from theta0 (GMR).


A data.frame with value pairs N, pwr for impact of deviations from planned N (dropouts).


Method of BE decision. Here fix = "NTID FDA".


Here fix = "FDA".


Minimum acceptable power from the call of the function.

The class 'pwrA' has the S3 methods print() and plot(). See pa.ABE for usage.


Be extremly carefull if your sample size plan has extremly small CV near or below 0.05 (5%). Adapt in that case your expected true ratio (theta0) to values nearer to 1 to not run into errors and/or long execution times.


The code for impact of deviations from planned sample size tries to keep the degree of imbalance as low as possible between (sequence) groups. This results in a lesser decrease of power than more extreme dropout-patterns.


D. Labes according to code by H. Schütz for pa.ABE() and pa.scABE().


Food and Drug Administration, Office of Generic Drugs (OGD). Draft Guidance on Warfarin Sodium. Recommended Dec 2012. download

Yu LX, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann DJ, Muldowney L, Chen ML, Davit B, Conner D, Woodcock J. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286–91. doi: 10.1002/cpt.28

Jiang W, Makhlouf F, Schuirmann DJ, Zhang X, Zheng N, Conner D, Yu LX, Lionberger R. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion. AAPS J. 2015;17(4):891–901. doi: 10.1208/s12248-015-9753-5

Endrényi L, Tóthfalusi L. Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden. J Pharm Pharm Sci. 2013;16(5):676–82. open access

See Also

power.NTIDFDA, print.pwrA, plot.pwrA, pa.ABE, pa.scABE


# using the defaults:
# targetpower=0.8, minpower=0.7, theta0/GMR=0.975
# BE margins from defaults of sampleN.NTIDFDA() 0.9002 ... 1.1108
# 1E5 sims in power.NTIDFDA()
# not run due to timing policy of CRAN for examples
# may run some ten seconds or more


PowerTOST documentation built on Jan. 18, 2021, 5:07 p.m.